Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.48% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Vanda Pharmaceuticals
VNDA
$304M
| $56.7M | 0.04% |
3,453,112
+244,772
| +8% | +$3.7M |
|
477
Alaska Air
ALK
$5.3B
| $56.4M | 0.04% |
832,327
+665,427
| +399% | +$45.4M |
|
|
GOOD
478
Gladstone Commercial Corp
GOOD
$641M
| $56.3M | 0.04% |
2,573,300
-20,700
| -0.8% | -$470K |
|
479
Ormat Technologies
ORA
$6.98B
| $56.2M | 0.04% |
754,700
-90,700
| -11% | -$6.87M |
|
480
SEI Investments
SEIC
$12.8B
| $56M | 0.04% |
855,400
-124,026
| -13% | -$7.71M |
|
|
NXRT
481
NexPoint Residential Trust
NXRT
$636M
| $56M | 0.04% |
1,243,500
| – | – |
|
482
Malibu Boats
MBUU
$573M
| $55.9M | 0.04% |
1,364,201
+142,900
| +12% | +$5.17M |
|
483
Murphy USA
MUSA
$10.4B
| $55.7M | 0.04% |
475,800
+92,500
| +24% | +$9.98M |
|
484
FNB Corp
FNB
$6.88B
| $55.7M | 0.04% |
4,383,328
+722,000
| +20% | +$8.85M |
|
485
Trane Technologies
TT
$105B
| $55.6M | 0.04% |
418,168
+169,903
| +68% | +$21.5M |
|
486
RB Global
RBA
$16B
| $55.4M | 0.04% |
1,288,897
+530,997
| +70% | +$22.1M |
|
487
Manhattan Associates
MANH
$11.7B
| $55.3M | 0.04% |
692,980
+331,020
| +91% | +$26.3M |
|
|
MODV
488
DELISTED
ModivCare
MODV
| $55.1M | 0.04% |
930,699
-32,621
| -3% | -$1.99M |
|
489
Check Point Software Technologies
CHKP
$13.7B
| $54.9M | 0.04% |
495,183
+413,583
| +507% | +$46.5M |
|
490
Clearway Energy Class C
CWEN
$7.02B
| $54.9M | 0.04% |
2,750,775
+363,997
| +15% | +$7.05M |
|
|
IMGN
491
DELISTED
Immunogen Inc
IMGN
| $54.7M | 0.04% |
10,707,139
+2,184,100
| +26% | +$7.41M |
|
492
Methanex
MEOH
$4.19B
| $54.5M | 0.04% |
1,410,348
+332,600
| +31% | +$12.5M |
|
493
Enphase Energy
ENPH
$5.39B
| $54.3M | 0.04% |
2,078,857
+1,956,157
| +1,594% | +$44.5M |
|
|
TARO
494
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $54.2M | 0.04% |
616,400
+34,700
| +6% | +$2.93M |
|
495
Par Pacific Holdings
PARR
$4.12B
| $54.1M | 0.04% |
2,326,447
+611,847
| +36% | +$14.6M |
|
496
American Financial Group
AFG
$12.1B
| $53.9M | 0.04% |
491,809
-299,106
| -38% | -$32M |
|
497
TIM SA
TIMB
$8.27B
| $53.9M | 0.04% |
2,821,298
-1,259,726
| -31% | -$19.9M |
|
498
Eversource Energy
ES
$27.2B
| $53.5M | 0.04% |
629,249
-1,224,222
| -66% | -$102M |
|
499
Ecolab
ECL
$77.4B
| $53.4M | 0.04% |
+276,922
| New | +$52.6M |
|
|
LMNX
500
DELISTED
Luminex Corp
LMNX
| $53.2M | 0.04% |
2,295,442
+74,700
| +3% | +$1.54M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.